Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 8/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.40 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL179212 | 0.94 | IDO1 (0.44) | CA12CA1CA2CA9KCNMA1 | |
| SCHEMBL10174151 | 0.91 | TRPV4 (0.45) | KCNMA1IDO1KMT2AMEN1KDR | |
| SCHEMBL147502 | 0.87 | IDO1 (0.44) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL147503 | 0.87 | IDO1 (0.44) | CA12CA1CA2CA9IDO1 | |
| SCHEMBL179225 | 0.85 | IDO1 (0.44) | KCNMA1IDO1KMT2AMEN1KDR | |
| SCHEMBL15444352 | 0.84 | IDO1 (0.45) | IDO1CYP3A4CYP2C9TDO2IDO2 | |
| SCHEMBL22746608 | 0.84 | ZAP70 (0.44) | KCNMA1IDO1KMT2AMEN1KDR | |
| SCHEMBL20198999 | 0.84 | IDO1 (0.46) | KCNMA1IDO1KMT2AMEN1KDR | |
| SCHEMBL18122516 | 0.84 | IDO1 (0.50) | CA12CA1CA2CA9KCNMA1 | |
| SCHEMBL1823400 | 0.84 | IDO1 (0.39) | IDO1CYP3A4CYP2C9TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2021-07-29 | — | — | US | disclosed |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2021-04-06 | — | — | US | disclosed |
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2019-08-06 | — | — | US | disclosed |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2018-07-31 | — | — | US | disclosed |
| US-10034939-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | THE UNIVERSITY OF CHICAGO (US) | 2018-07-31 | — | — | US | disclosed |
| US-20180177769-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2018-06-28 | — | — | US | disclosed |
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-9789094-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE HOLDINGS CORPORATION (US) | 2017-10-17 | — | — | US | disclosed |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION | 2016-08-04 | — | — | US | disclosed |
| US-9320732-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF CHICAGO (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2015-07-09 | — | — | US | disclosed |
| US-8993605-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2015-03-31 | — | — | US | disclosed |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | INCYTE CORPORATION (US) | 2014-10-23 | — | — | US | disclosed |
| US-8822511-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-09-02 | — | — | US | disclosed |
| US-8796319-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | INCYTE CORPORATION (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION (US) | 2014-01-23 | — | — | US | disclosed |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | INCYTE CORPORATION, A DELAWARE CORPORATION | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210030722-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20140315962-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-10369137-B2 | 1,2,5-Oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-11207302-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-10034864-B2 | 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20140023663-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20170348289-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20150352206-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | CA12 1918/4885CA1 1086/4885CA2 1149/4885 |
| US-20210228715-A1 | SYNERGISTIC COMBINATION OF IMMUNOLOGIC INHIBITORS FOR THE TREATMENT OF CANCER | ICOS, CD274, IDO1 | CA12 1918/4885CA1 1086/4885CA2 1149/4885 |
| US-20150190378-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20160220543-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-20120058079-A1 | 1,2,5-Oxadiazoles as Inhibitors of Indoleamine 2,3-Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
| US-10967060-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, IDO1, IL2 | CA12 3150/4885CA1 2170/4885CA2 1944/4885 |
| US-10034939-B2 | Synergistic combination of immunologic inhibitors for the treatment of cancer | ICOS, CD274, IDO1 | CA12 1918/4885CA1 1086/4885CA2 1149/4885 |
| US-20180177769-A1 | 1,2,5-Oxadiazoles As Inhibitors Of Indoleamine 2,3- Dioxygenase | IDO1, IDO2, INMT | CA12 3155/4885CA1 1715/4885CA2 1553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.